Candesartan Cilexetil

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure[1][2][3][4][5][6].

Product Specifications

CAS Number

[145040-37-5]

Product Name Alternative

TCV-116

UNSPSC

12352005

Hazard Statement

H361, H400

Target

Angiotensin Receptor; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Candesartan-Cilexetil.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(C1=C2C(N=C(OCC)N2CC3=CC=C(C4=CC=CC=C4C5=NNN=N5)C=C3)=CC=C1)OC(OC(OC6CCCCC6)=O)C

Molecular Formula

C33H34N6O6

Molecular Weight

610.66

Precautions

H361, H400

References & Citations

[1]Loe M W C, et al. Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection [J]. Antiviral Research, 2019, 172: 104637.|[2]Kobayashi N, et al. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats [J]. Atherosclerosis, 2001, 156 (2) : 255-265.|[3]Takeda H, et al. Effects of angiotensin II receptor signaling during skin wound healing [J]. The American journal of pathology, 2004, 165 (5) : 1653-1662.|[4]McClellan K J, et al. Candesartan cilexetil: a review of its use in essential hypertension [J]. Drugs, 1998, 56: 847-869.|[5]Kojima M, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro [J]. Circulation, 1994, 89 (5) : 2204-2211.|[6]Otsuka M, et al. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist [J]. Thorax, 2004, 59 (1) : 31-38.